Cytel is one of the leading global providers of clinical trial design SaaS software, biometric services and advanced analytics, focusing on optimising clinical trials and helping pharmaceutical companies to unlock the full potential of their clinical and real-world data.

Building on Cytel’s advanced software platform and leading biometrics services offerings, Nordic Capital will invest in the continued development of the business and its software with the ambition to actively support and accelerate Cytel’s next phase of growth and innovation.